Showing 911-920 of 1201 results for "".
- Trend Alert: New Allergan Aesthetics Report Highlights What’s to Comehttps://modernaesthetics.com/news/trend-alert-new-allergan-aesthetics-report-highlights-whats-to-come/2473254/Consumer interest in medical aesthetics continues to rise, with the number of dermal filler treatments worldwide growing by almost two million between 2017 and 2020, according to Allergan Aesthetics’ 'The Future of Aesthetics' global trends report. In addition, the r
- Apyx Medical Corporation Scores FDA 510(k) Clearance for Renuvion Handpiecehttps://modernaesthetics.com/news/apyx-medical-corporation-scores-fda-510k-clearance-for-renuvion-handpiece/2473245/The U.S. Food and Drug Administration has granted marketing clearance to Apyx Medical Corporation’s Renuvion Dermal Handpiece for specific dermal resurfacing procedures. The Renuvion Dermal Handpiece is indicated for dermatological procedures for the treatment of moderate to
- Colorescience Finishing Touch Protocol Boosts Patient Satisfaction after Microneedling RFhttps://modernaesthetics.com/news/colorescience-finishing-touch-protocol-boosts-patient-satisfaction-after-microneedling-rf/2473243/Colorescience’s Finishing Touch post-treatment skincare protocol improves patient confidence, comfort, satisfaction, and increases the likelihood of a repeat radiofrequency microneedling procedure, according to research in The Journal of Clinical and Aesthetic Dermatology
- ISHRS Survey: Surgical Advances; Improvements in Efficiency Driving Need for Fewer Hair Transplant Treatmentshttps://modernaesthetics.com/news/ishrs-survey-surgical-advances-improvements-in-efficiency-driving-need-for-fewer-hair-transplant-treatments/2473235/According to results of a new member survey conducted by the International Society of Hair Restoration Surgery (ISHRS), 68 percent of members reported performing an average of one procedure per patient in 2021 to achieve the desired hair restoration result. This represents a significant improveme
- Meet Avéli, Cellulite's Latest Foehttps://modernaesthetics.com/news/meet-aveli-cellulites-latest-foe/2473234/Revelle Aesthetics, In
- CellFX from Pulse Biosciences Shows Durable Effects for Sebaceous Hyperplasia: ASLMS Presentationhttps://modernaesthetics.com/news/cellfx-from-pulse-biosciences-shows-durable-effects-for-sebaceous-hyperplasia-aslms-presentation/2473233/The CellFX® system from Pulse Biosciences, Inc. demonstrates durable efficacy for the clearance of Sebaceous Hyperplasia lesions, according to data presented at the 2022
- Revance News: FDA Accepts BLA Resubmission for DaxibotulinumtoxinAhttps://modernaesthetics.com/news/revance-news-fda-accepts-bla-resubmission-for-daxibotulinumtoxina/2473223/The U.S. Food and Drug Administration (FDA) accepted Revance’s Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The FDA designated the BLA as a Class 2 resubmission, which has a six-mont
- Study: Sick Patients Get Cosmetic Surgery to Look Healthierhttps://modernaesthetics.com/news/study-sick-patients-get-cosmetic-surgery-to-look-healthier/2473216/Patients dealing with serious illnesses may want cosmetic procedures to make them look healthier, reports a small new Northwestern Medicine study. The patients believe cosmetic surgery may help them feel better in social situations with their friends, family or when they’re at work. &n
- PatientFi, Allergan Expand Co-marketing Agreementhttps://modernaesthetics.com/news/patientfi-allergan-expand-co-marketing-agreement/2473214/PatientFi® is expanding its co-marketing agreement with Allergan Aesthetics, an AbbVie company, to provide financing options for patients interested in treatments such as BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM®Collection of Fillers, Natrelle® breast i
- Aquavit's Neurotoxin Submitted to FDAhttps://modernaesthetics.com/news/aquavits-neurotoxin-submitted-to-fda/2473213/Aquavit Pharmaceuticals, Inc. has submitted its IND for a new botulinum toxin (DTX-021) to the FDA for approval. The company also unveiled its development programs at the Annual meeting of the American Academy of Dermatology in Boston. DTX-021, a botulinum toxin type A drug intende